Trade Elicit Therapeutics Inc. - ELTX CFD

Angion Biomedica Corp. Company profile

About Angion Biomedica Corp

Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Financial summary

BRIEF: For the nine months ended 30 September 2021, Angion Biomedica Corp revenues decreased 2% to $2.4M. Net loss increased 36% to $69.5M. Revenues reflect Grant revenue decrease from $2.4M to $0K. Higher net loss reflects Research and development - Balancing increase of 40% to $36.9M (expense), Other Non Operati decrease from $10K (income) to $3.6M (expense), Stock-based Compensation in R&D increase from $1.6M to $5.1M (expense).